DC Circuit tightens US FDA test for retaining Hatch-Waxman exclusivity
The US Court of Appeals for the DC Circuit found last week that the Food and Drug Administration applied the wrong causation standard when considering forfeiture of the 180-day exclusivity period...To view the full article, register now.
Already a subscriber? Click here to view full article